Revaprazan
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01750437)
Timeline
Indications
Mechanism of action
ATP12A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C- Mol. weight
- 362.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1618279 ↗
- ChEMBLCHEMBL1257753 ↗
Also known as
- 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
- revanex
- revaprazan
- revaprazan
- revaprazan
- revaprazan
- revaprazan
- revaprazan hcl
- revaprazan hydrochloride
- revaprazan hydrochloride
- revaprazan hydrochloride
- revaprazan hydrochloride
- revaprazan hydrochloride
- yh1885
- yh 1885
- yh 1885
- yh-1885
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03378284 | Phase 1 | Dec 10, 2017 | CJ HealthCare Corp., Seoul National University |
| NCT01750437 | Phase 2 | Jan 1, 2013 | Yuhan Pharmaceutical Company |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CJ HealthCare Corp. | For profit | 1 | 1 | 1 | 2017 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Yuhan Pharmaceutical Company | For profit | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1